Synthetic circRNA therapeutics: innovations, strategies, and future horizons
Citations Over TimeTop 10% of 2024 papers
Abstract
Small molecule drugs are increasingly emerging as innovative and effective treatments for various diseases, with mRNA therapeutics being a notable representative. The success of COVID-19 vaccines has underscored the transformative potential of mRNA in RNA therapeutics. Within the RNA family, there is another unique type known as circRNA. This single-stranded closed-loop RNA molecule offers notable advantages over mRNA, including enhanced stability and prolonged protein expression, which may significantly impact therapeutic strategies. Furthermore, circRNA plays a pivotal role in the pathogenesis of various diseases, such as cancers, autoimmune disorders, and cardiovascular diseases, making it a promising clinical intervention target. Despite these benefits, the application of circRNA in clinical settings remains underexplored. This review provides a comprehensive overview of the current state of synthetic circRNA therapeutics, focusing on its synthesis, optimization, delivery, and diverse applications. It also addresses the challenges impeding the advancement of circRNA therapeutics from bench to bedside. By summarizing these aspects, the review aims to equip researchers with insights into the ongoing developments and future directions in circRNA therapeutics. Highlighting both the progress and the existing gaps in circRNA research, this review offers valuable perspectives for advancing the field and guiding future investigations.
Related Papers
- → The age of biomedicine: current trends in traditional subjects(2011)30 cited
- Bigger is Not Always Better: Should Educators Aim For Big Transformative Learning Events or Small Transformative Experiences?(2015)
- → Knowledge discovery and computer-based decision support in biomedicine(2010)4 cited
- → Transformative Valuing(2020)1 cited
- → A Case Study of Transformative Learning of College English Teachers(2020)